28 May 2022 in Clinical and Experimental Dermatology
Acne vulgaris is an extremely common disorder of the pilosebaceous unit, typically manifest as a highly visible facial and upper trunk dermatosis, with teenagers most frequently affected. This cohort is markedly susceptible to misinformation, given their impressionable age, distress about their appearance and high internet usage. This study aimed to assess the content of acne-related misinformation available online. A formal review of PubMed was performed in March 2022, using the terms 'acne' AND 'misinformation' OR 'disinformation' OR 'conspiracy theory', along with an informal Google search using combinations of these terms, and further targeted searches on TikTok, Twitter, Facebook and Instagram. Key themes of acne-related misinformation included diet and other 'causes' of acne, unconventional acne 'cures' and a distrust of conventional acne treatments. Websites promoting misinformation were frequently affiliated with companies selling products that promised to cure acne, often in a remarkably short time. Dermatologists should be aware of the nature of acne-related misinformation available online and be prepared to counter it with scientific principles and facts.
16 May 2022 in Skin Health and Disease
Lichen sclerosus (LS) is a chronic inflammatory dermatosis predominantly affecting the anogenital region, which can have significant impact on quality of life. Burden of treatment (BOT) is defined as the workload of healthcare experienced by patients and consequences on well-being. In this prospective study, 35 women with vulval LS completed a detailed Treatment Burden Questionnaire to assess their BOT. Nineteen (54.3%) achieved a score of 35 or less, signifying low BOT; ten (28.6%) between 36 and 65, signifying moderate BOT; and six (17.1%) above 65, signifying high BOT. Seven (20%) patients reported BOT scores of greater than 59, which has been designated as a cut-off for increased risk of treatment-related burnout. Higher BOT scores were moderately correlated with higher DLQI scores (r = 0.47, p < 0.01). BOT in LS is low for most patients, although a minority are at risk of treatment-related burnout. BOT should be considered when forming treatment guidelines for LS.
4 January 2020 in Photodermatology, Photoimmunology & Photomedicine
18 June 2020 in Australasian Journal of Dermatology
8 August 2020 in Dermatologic Therapy
Click on the article title to read more.
21 January 2020 in JCR: Journal of Clinical Rheumatology
An abstract is unavailable. This article is available as a PDF only.